ILMN (Illumina) EV/Sales Multiple

illumina.com (ILMN) - corporate logo

Illumina, Inc. (ILMN) management is undergoing a deep overhaul following corporate disputes. Illumina, Inc. (ILMN) maintains its leadership in DNA sequencing by monetizing the sale of consumables. Stable demand for reagents ensures a steady cash flow. The latest parameter is 6894.55, which clearly demonstrates the change in the EV/Sales ratio on this chart below.

Illumina, Inc. (ILMN) EV/Sales Multiple: for the period 11/23/2025 - 11/20/2026

Illumina Inc - analytical breakdowns and key metrics (ILMN)

- share price and expert price forecast:
- cash and cash flow indicators:
Fundamental valuation:Illumina, Inc. ILMN
Finished products of Illumina

Capital seeks to decouple sustainable business from speculative ventures, utilizing EV/Sales to assess business value relative to revenue regardless of debt load. The "razor-and-blade" model of Illumina, Inc. (ILMN), driven by recurring consumable sales, ensures a stable cash flow, making this multiple a key indicator of fundamental value. The narrowing amplitude on this EV/Sales chart signals a temporary equilibrium in market expectations ahead of a potential impulse.

Competitor analysis for Illumina, Inc.

A (Agilent) - Company Value to Revenue Ratio|DGX (Quest Diagnostics) - Company Value to Revenue|Company Value to Revenue Cologuard|RVTY (Revvity Corp) - EV/Sales Multiple|EV/Sales Multiple Bio-Rad Laboratories Inc|Company Value to Revenue NNNN (Anbio Biotechnology)|SHC (Sotera Health Company) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio QuidelOrtho Inc. QDEL|EV/Sales Multiple OPKO Health Inc OPK|CareDx Inc - EV/Sales Multiple|Business Value to Revenue MRVI (Maravai)|FLGT: EV/Sales Multiple|LAB (Standard BioTools Inc.) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Cytek Biosciences Inc|Enterprise Value-to-Revenue Multiple OraSure OSUR|Company Value to Revenue XGN (Exagen Diagnostics)|Total Company Value-to-Revenue Ratio MDxHealth Inc.|Enterprise Value-to-Revenue Ratio Lucid Diagnostics, Inc. LUCD|Prenetics Global Ltd (PRE) - Enterprise Value-to-Revenue Multiple|Insight Molecular Diagnostics Inc - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple trinitybiotech.com|PRPH (ProPhase) - Company Value to Revenue|Company Value to Revenue Ratio AIMD|Company Value to Revenue CODX|Enterprise Value-to-Revenue Multiple heartsciences.com HSCS|Enterprise Value-to-Revenue Ratio Biomerica Inc. (BMRA)|Total Company Value-to-Revenue Ratio Cardio Diagnostics Holdings|EV/Sales Multiple ONCO (Onconetix Corporation)|Virax Biolabs Group (VRAX) - Enterprise Value-to-Revenue Multiple|bluejaydx.com - EV/Sales Multiple|Aspira Women's Health - Enterprise Value-to-Revenue Coefficient|AXDX (Accelerate Diagnostics) - Company Value to Revenue|Company Value to Revenue CENTOGENE, N.V.|Enterprise Value-to-Revenue Ratio enzo.com|EV/Sales Multiple Fresh2 Group Limited|EV/Sales Multiple GENE|23andMe Holding Co. - Company Value to Revenue Ratio|Psychemedics Inc - Company Value to Revenue